Shopping Cart 0
Cart Subtotal
USD 0

Respiratory Tract Infections Drug Development Pipeline Review, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 11985

Details

Respiratory Tract Infections Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for tuberculosis, diphtheria and pertussis (whooping cough), and features dormant and discontinued products.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in the body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. There are 206 products in development for this indication.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics. There are 31 products in development for this indication.

Pertussis is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. There are 40 products in development for this indication.

Molecular targets acted on by products in development for respiratory tract infections include bacterial proteins and toxins. Companies operating in this pipeline space include Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline.

Scope

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Respiratory Tract Infections Report Coverage 8

2.2 Tuberculosis-Overview 8

2.3 Diphtheria-Overview 8

2.4 Pertussis (Whooping Cough)-Overview 8

3 Therapeutics Development 9

3.1 Tuberculosis 9

3.2 Diphtheria 25

3.3 Pertussis (Whooping Cough) 32

4 Therapeutics Assessment 40

4.1 Tuberculosis 40

4.2 Diphtheria 49

4.3 Pertussis (Whooping Cough) 53

5 Companies Involved in Therapeutics Development 58

5.1 Tuberculosis 58

5.2 Diphtheria 86

5.3 Pertussis (Whooping Cough) 94

6 Dormant Projects 105

6.1 Tuberculosis 105

6.2 Diphtheria 112

6.3 Pertussis (Whooping Cough) 114

7 Discontinued Products 117

7.1 Tuberculosis 117

7.2 Diphtheria 117

7.3 Pertussis (Whooping Cough) 117

8 Product Development Milestones 118

8.1 Tuberculosis 118

8.2 Diphtheria 129

8.3 Pertussis (Whooping Cough) 138

9 Appendix 152

9.1 Methodology 152

9.2 Coverage 152

9.3 Secondary Research 152

9.4 Primary Research 152

9.5 Expert Panel Validation 152

9.6 Contact Us 153

9.7 Disclaimer 153


List Of Figure

1.2 List of Figures

Figure 1: Number of Products under Development for Tuberculosis 9

Figure 2: Number of Products under Development by Companies Tuberculosis 10

Figure 3: Number of Products under Development by Universities/Institutes Tuberculosis 13

Figure 4: Number of Products under Development for Diphtheria 25

Figure 5: Number of Products under Development by Companies Diphtheria 26

Figure 6: Number of Products under Development by Universities/Institutes Diphtheria 28

Figure 7: Number of Products under Development for Pertussis (Whooping Cough) 32

Figure 8: Number of Products under Development by Companies Pertussis (Whooping Cough) 33

Figure 9: Number of Products under Development by Universities/Institutes Pertussis (Whooping Cough) 35

Figure 10: Number of Products by Top 10 Targets Tuberculosis 40

Figure 11: Number of Products by Stage and Top 10 Targets Tuberculosis 40

Figure 12: Number of Products by Top 10 Mechanism of Actions Tuberculosis 43

Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions Tuberculosis 43

Figure 14: Number of Products by Routes of Administration Tuberculosis 46

Figure 15: Number of Products by Stage and Routes of Administration Tuberculosis 46

Figure 16: Number of Products by Top 10 Molecule Types Tuberculosis 47

Figure 17: Number of Products by Stage and Top 10 Molecule Types Tuberculosis 48

Figure 18: Number of Products by Targets Diphtheria 49

Figure 19: Number of Products by Stage and Targets Diphtheria 49

Figure 20: Number of Products by Routes of Administration Diphtheria 50

Figure 21: Number of Products by Stage and Routes of Administration Diphtheria 51

Figure 22: Number of Products by Molecule Types Diphtheria 52

Figure 23: Number of Products by Stage and Molecule Types Diphtheria 52

Figure 24: Number of Products by Targets Pertussis (Whooping Cough) 53

Figure 25: Number of Products by Stage and Targets Pertussis (Whooping Cough) 54

Figure 26: Number of Products by Routes of Administration Pertussis (Whooping Cough) 55

Figure 27: Number of Products by Stage and Routes of Administration Pertussis (Whooping Cough) 55

Figure 28: Number of Products by Top 10 Molecule Types Pertussis (Whooping Cough) 56

Figure 29: Number of Products by Stage and Molecule Types Pertussis (Whooping Cough) 57


List Of Table

1.1 List of Tables

Table 1: Number of Products under Development for Tuberculosis 9

Table 2: Number of Products under Development by Companies Tuberculosis 11

Table 3: Number of Products under Development by Universities/Institutes Tuberculosis 14

Table 4: Products under Development by Companies Tuberculosis 16

Table 5: Products under Development by Universities/Institutes Tuberculosis 21

Table 6: Number of Products under Development for Diphtheria 25

Table 7: Number of Products under Development by Companies Diphtheria 27

Table 8: Number of Products under Development by Universities/Institutes Diphtheria 28

Table 9: Products under Development by Companies Diphtheria 29

Table 10: Products under Development by Universities/Institutes Diphtheria 31

Table 11: Number of Products under Development for Pertussis (Whooping Cough) 32

Table 12: Number of Products under Development by Companies Pertussis (Whooping Cough) 34

Table 13: Number of Products under Development by Universities/Institutes Pertussis (Whooping Cough) 35

Table 14: Products under Development by Companies Pertussis (Whooping Cough) 36

Table 15: Products under Development by Universities/Institutes Pertussis (Whooping Cough) 39

Table 16: Number of Products by Stage and Target Tuberculosis 41

Table 17: Number of Products by Stage and Mechanism of Action Tuberculosis 44

Table 18: Number of Products by Stage and Route of Administration Tuberculosis 47

Table 19: Number of Products by Stage and Molecule Type Tuberculosis 48

Table 20: Number of Products by Stage and Target Diphtheria 50

Table 21: Number of Products by Stage and Route of Administration Diphtheria 51

Table 22: Number of Products by Stage and Molecule Type Diphtheria 53

Table 23: Number of Products by Stage and Target Pertussis (Whooping Cough) 54

Table 24: Number of Products by Stage and Mechanism of Action Pertussis (Whooping Cough) 54

Table 25: Number of Products by Stage and Route of Administration Pertussis (Whooping Cough) 56

Table 26: Number of Products by Stage and Molecule Type Pertussis (Whooping Cough) 57

Table 27: Tuberculosis-Pipeline by Abera Bioscience AB 58

Table 28: Tuberculosis-Pipeline by AGILeBiotics BV 58

Table 29: Tuberculosis-Pipeline by Akshaya Bio Inc 59

Table 30: Tuberculosis-Pipeline by Archivel Farma SL 59

Table 31: Tuberculosis-Pipeline by AstraZeneca Plc 60

Table 32: Tuberculosis-Pipeline by Aucta Pharmaceuticals LLC 60

Table 33: Tuberculosis-Pipeline by BioLingus AG 61

Table 34: Tuberculosis-Pipeline by Bioversys AG 61

Table 35: Tuberculosis-Pipeline by Celgene Corp 62

Table 36: Tuberculosis-Pipeline by Chongqing Zhifei Biological Products Co Ltd 62

Table 37: Tuberculosis-Pipeline by Consegna Pharma Inc 63

Table 38: Tuberculosis-Pipeline by Crestone Inc 63

Table 39: Tuberculosis-Pipeline by Daiichi Sankyo Co Ltd 64

Table 40: Tuberculosis-Pipeline by Demuris Ltd 64

Table 41: Tuberculosis-Pipeline by Eisai Co Ltd 65

Table 42: Tuberculosis-Pipeline by Eli Lilly and Co 65

Table 43: Tuberculosis-Pipeline by EpiVax Inc 66

Table 44: Tuberculosis-Pipeline by Evotec AG 66

Table 45: Tuberculosis-Pipeline by FIT Biotech Oy 67

Table 46: Tuberculosis-Pipeline by GangaGen Inc 67

Table 47: Tuberculosis-Pipeline by GC Pharma 68

Table 48: Tuberculosis-Pipeline by GlaxoSmithKline Plc 68

Table 49: Tuberculosis-Pipeline by Globeimmune Inc 69

Table 50: Tuberculosis-Pipeline by Hager Biosciences LLC 69

Table 51: Tuberculosis-Pipeline by Hsiri Therapeutics LLC 70

Table 52: Tuberculosis-Pipeline by Immodulon Therapeutics Ltd 70

Table 53: Tuberculosis-Pipeline by Immunitor Inc 71

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Abera Bioscience AB

AGILeBiotics BV

Akshaya Bio Inc

Archivel Farma SL

AstraZeneca Plc

Aucta Pharmaceuticals LLC

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

BioLingus AG

Biological E Ltd

Bioversys AG

BlueWillow Biologics

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Celgene Corp

Chongqing Zhifei Biological Products Co Ltd

Consegna Pharma Inc

Crestone Inc

Daiichi Sankyo Co Ltd

DBV Technologies SA

Demuris Ltd

Diphtheria

Eisai Co Ltd

Eli Lilly and Co

EpiVax Inc

Evotec AG

FIT Biotech Oy

GangaGen Inc

GC Pharma

GlaxoSmithKline Plc

Globeimmune Inc

Hager Biosciences LLC

Hsiri Therapeutics LLC

Immodulon Therapeutics Ltd

Immunitor Inc

ImmunoBiology Ltd

Indian Immunologicals Ltd

Innovare R & D SA De CV

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kaketsuken

LegoChem Biosciences Inc

LG Chem Ltd

Matinas BioPharma Holdings Inc

Merck & Co Inc

Microbiotix Inc

Novartis AG

NovoBiotic Pharmaceuticals LLC

Otsuka Holdings Co Ltd

Panacea Biotec Ltd

Pertussis (Whooping Cough)

Pfizer Inc

QureTech Bio AB

Qurient Co Ltd

Recce Ltd

Rodos BioTarget GmbH

Sanofi

Sanofi Pasteur SA

Sequella Inc

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Shionogi & Co Ltd

Synthetic Biologics Inc

Takeda Pharmaceutical Co Ltd

Target Medicals LLC

Theravectys SA

TVAX Biomedical Inc

Vaccibody AS

Vakzine Projekt Management GmbH

Vaxil Bio Therapeutics Ltd

Vaxine Pty Ltd

Vichem Chemie Research Ltd

Wockhardt Ltd

Company Profile

Company Profile Title

Respiratory Tract Infections Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for tuberculosis, diphtheria and pertussis (whooping cough), and features dormant and discontinued products.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in the body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. There are 206 products in development for this indication.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics. There are 31 products in development for this indication.

Pertussis is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. There are 40 products in development for this indication.

Molecular targets acted on by products in development for respiratory tract infections include bacterial proteins and toxins. Companies operating in this pipeline space include Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline.

Scope

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

READ MORE

Scope

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Respiratory Tract Infections Report Coverage 8

2.2 Tuberculosis-Overview 8

2.3 Diphtheria-Overview 8

2.4 Pertussis (Whooping Cough)-Overview 8

3 Therapeutics Development 9

3.1 Tuberculosis 9

3.2 Diphtheria 25

3.3 Pertussis (Whooping Cough) 32

4 Therapeutics Assessment 40

4.1 Tuberculosis 40

4.2 Diphtheria 49

4.3 Pertussis (Whooping Cough) 53

5 Companies Involved in Therapeutics Development 58

5.1 Tuberculosis 58

5.2 Diphtheria 86

5.3 Pertussis (Whooping Cough) 94

6 Dormant Projects 105

6.1 Tuberculosis 105

6.2 Diphtheria 112

6.3 Pertussis (Whooping Cough) 114

7 Discontinued Products 117

7.1 Tuberculosis 117

7.2 Diphtheria 117

7.3 Pertussis (Whooping Cough) 117

8 Product Development Milestones 118

8.1 Tuberculosis 118

8.2 Diphtheria 129

8.3 Pertussis (Whooping Cough) 138

9 Appendix 152

9.1 Methodology 152

9.2 Coverage 152

9.3 Secondary Research 152

9.4 Primary Research 152

9.5 Expert Panel Validation 152

9.6 Contact Us 153

9.7 Disclaimer 153


List Of Figure

1.2 List of Figures

Figure 1: Number of Products under Development for Tuberculosis 9

Figure 2: Number of Products under Development by Companies Tuberculosis 10

Figure 3: Number of Products under Development by Universities/Institutes Tuberculosis 13

Figure 4: Number of Products under Development for Diphtheria 25

Figure 5: Number of Products under Development by Companies Diphtheria 26

Figure 6: Number of Products under Development by Universities/Institutes Diphtheria 28

Figure 7: Number of Products under Development for Pertussis (Whooping Cough) 32

Figure 8: Number of Products under Development by Companies Pertussis (Whooping Cough) 33

Figure 9: Number of Products under Development by Universities/Institutes Pertussis (Whooping Cough) 35

Figure 10: Number of Products by Top 10 Targets Tuberculosis 40

Figure 11: Number of Products by Stage and Top 10 Targets Tuberculosis 40

Figure 12: Number of Products by Top 10 Mechanism of Actions Tuberculosis 43

Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions Tuberculosis 43

Figure 14: Number of Products by Routes of Administration Tuberculosis 46

Figure 15: Number of Products by Stage and Routes of Administration Tuberculosis 46

Figure 16: Number of Products by Top 10 Molecule Types Tuberculosis 47

Figure 17: Number of Products by Stage and Top 10 Molecule Types Tuberculosis 48

Figure 18: Number of Products by Targets Diphtheria 49

Figure 19: Number of Products by Stage and Targets Diphtheria 49

Figure 20: Number of Products by Routes of Administration Diphtheria 50

Figure 21: Number of Products by Stage and Routes of Administration Diphtheria 51

Figure 22: Number of Products by Molecule Types Diphtheria 52

Figure 23: Number of Products by Stage and Molecule Types Diphtheria 52

Figure 24: Number of Products by Targets Pertussis (Whooping Cough) 53

Figure 25: Number of Products by Stage and Targets Pertussis (Whooping Cough) 54

Figure 26: Number of Products by Routes of Administration Pertussis (Whooping Cough) 55

Figure 27: Number of Products by Stage and Routes of Administration Pertussis (Whooping Cough) 55

Figure 28: Number of Products by Top 10 Molecule Types Pertussis (Whooping Cough) 56

Figure 29: Number of Products by Stage and Molecule Types Pertussis (Whooping Cough) 57


List Of Table

1.1 List of Tables

Table 1: Number of Products under Development for Tuberculosis 9

Table 2: Number of Products under Development by Companies Tuberculosis 11

Table 3: Number of Products under Development by Universities/Institutes Tuberculosis 14

Table 4: Products under Development by Companies Tuberculosis 16

Table 5: Products under Development by Universities/Institutes Tuberculosis 21

Table 6: Number of Products under Development for Diphtheria 25

Table 7: Number of Products under Development by Companies Diphtheria 27

Table 8: Number of Products under Development by Universities/Institutes Diphtheria 28

Table 9: Products under Development by Companies Diphtheria 29

Table 10: Products under Development by Universities/Institutes Diphtheria 31

Table 11: Number of Products under Development for Pertussis (Whooping Cough) 32

Table 12: Number of Products under Development by Companies Pertussis (Whooping Cough) 34

Table 13: Number of Products under Development by Universities/Institutes Pertussis (Whooping Cough) 35

Table 14: Products under Development by Companies Pertussis (Whooping Cough) 36

Table 15: Products under Development by Universities/Institutes Pertussis (Whooping Cough) 39

Table 16: Number of Products by Stage and Target Tuberculosis 41

Table 17: Number of Products by Stage and Mechanism of Action Tuberculosis 44

Table 18: Number of Products by Stage and Route of Administration Tuberculosis 47

Table 19: Number of Products by Stage and Molecule Type Tuberculosis 48

Table 20: Number of Products by Stage and Target Diphtheria 50

Table 21: Number of Products by Stage and Route of Administration Diphtheria 51

Table 22: Number of Products by Stage and Molecule Type Diphtheria 53

Table 23: Number of Products by Stage and Target Pertussis (Whooping Cough) 54

Table 24: Number of Products by Stage and Mechanism of Action Pertussis (Whooping Cough) 54

Table 25: Number of Products by Stage and Route of Administration Pertussis (Whooping Cough) 56

Table 26: Number of Products by Stage and Molecule Type Pertussis (Whooping Cough) 57

Table 27: Tuberculosis-Pipeline by Abera Bioscience AB 58

Table 28: Tuberculosis-Pipeline by AGILeBiotics BV 58

Table 29: Tuberculosis-Pipeline by Akshaya Bio Inc 59

Table 30: Tuberculosis-Pipeline by Archivel Farma SL 59

Table 31: Tuberculosis-Pipeline by AstraZeneca Plc 60

Table 32: Tuberculosis-Pipeline by Aucta Pharmaceuticals LLC 60

Table 33: Tuberculosis-Pipeline by BioLingus AG 61

Table 34: Tuberculosis-Pipeline by Bioversys AG 61

Table 35: Tuberculosis-Pipeline by Celgene Corp 62

Table 36: Tuberculosis-Pipeline by Chongqing Zhifei Biological Products Co Ltd 62

Table 37: Tuberculosis-Pipeline by Consegna Pharma Inc 63

Table 38: Tuberculosis-Pipeline by Crestone Inc 63

Table 39: Tuberculosis-Pipeline by Daiichi Sankyo Co Ltd 64

Table 40: Tuberculosis-Pipeline by Demuris Ltd 64

Table 41: Tuberculosis-Pipeline by Eisai Co Ltd 65

Table 42: Tuberculosis-Pipeline by Eli Lilly and Co 65

Table 43: Tuberculosis-Pipeline by EpiVax Inc 66

Table 44: Tuberculosis-Pipeline by Evotec AG 66

Table 45: Tuberculosis-Pipeline by FIT Biotech Oy 67

Table 46: Tuberculosis-Pipeline by GangaGen Inc 67

Table 47: Tuberculosis-Pipeline by GC Pharma 68

Table 48: Tuberculosis-Pipeline by GlaxoSmithKline Plc 68

Table 49: Tuberculosis-Pipeline by Globeimmune Inc 69

Table 50: Tuberculosis-Pipeline by Hager Biosciences LLC 69

Table 51: Tuberculosis-Pipeline by Hsiri Therapeutics LLC 70

Table 52: Tuberculosis-Pipeline by Immodulon Therapeutics Ltd 70

Table 53: Tuberculosis-Pipeline by Immunitor Inc 71

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Abera Bioscience AB

AGILeBiotics BV

Akshaya Bio Inc

Archivel Farma SL

AstraZeneca Plc

Aucta Pharmaceuticals LLC

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

BioLingus AG

Biological E Ltd

Bioversys AG

BlueWillow Biologics

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Celgene Corp

Chongqing Zhifei Biological Products Co Ltd

Consegna Pharma Inc

Crestone Inc

Daiichi Sankyo Co Ltd

DBV Technologies SA

Demuris Ltd

Diphtheria

Eisai Co Ltd

Eli Lilly and Co

EpiVax Inc

Evotec AG

FIT Biotech Oy

GangaGen Inc

GC Pharma

GlaxoSmithKline Plc

Globeimmune Inc

Hager Biosciences LLC

Hsiri Therapeutics LLC

Immodulon Therapeutics Ltd

Immunitor Inc

ImmunoBiology Ltd

Indian Immunologicals Ltd

Innovare R & D SA De CV

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kaketsuken

LegoChem Biosciences Inc

LG Chem Ltd

Matinas BioPharma Holdings Inc

Merck & Co Inc

Microbiotix Inc

Novartis AG

NovoBiotic Pharmaceuticals LLC

Otsuka Holdings Co Ltd

Panacea Biotec Ltd

Pertussis (Whooping Cough)

Pfizer Inc

QureTech Bio AB

Qurient Co Ltd

Recce Ltd

Rodos BioTarget GmbH

Sanofi

Sanofi Pasteur SA

Sequella Inc

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Shionogi & Co Ltd

Synthetic Biologics Inc

Takeda Pharmaceutical Co Ltd

Target Medicals LLC

Theravectys SA

TVAX Biomedical Inc

Vaccibody AS

Vakzine Projekt Management GmbH

Vaxil Bio Therapeutics Ltd

Vaxine Pty Ltd

Vichem Chemie Research Ltd

Wockhardt Ltd